secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001213900-26-023439
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL
--------------------------------------------------------------------------------

- ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.
- One-year PFS 77% (95% CI: 43–92%); one-year OS 84% (95% CI: 49–96%).
- Well-tolerated: no dose-limiting toxicities, no Grade≥3 LYMPHIR-related immune AEs.
- Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL).
- Study conducted at Univ of Minnesota and City of Hope; presented at 2026 Tandem Meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/0001213900-26-023439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea0277422-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-023439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer